Presentation is loading. Please wait.

Presentation is loading. Please wait.

Planning Committee Cheryl Lambing, MD, Co-Chair UCLA / Ventura County Medical Center Marjorie Luckey, MD, Co-Chair Saint Barnabas Medical Center Steven.

Similar presentations


Presentation on theme: "Planning Committee Cheryl Lambing, MD, Co-Chair UCLA / Ventura County Medical Center Marjorie Luckey, MD, Co-Chair Saint Barnabas Medical Center Steven."— Presentation transcript:

1

2 Planning Committee Cheryl Lambing, MD, Co-Chair UCLA / Ventura County Medical Center Marjorie Luckey, MD, Co-Chair Saint Barnabas Medical Center Steven T. Harris, MD University of California, San Francisco Pamela Kushner, MD University of California, Irvine Diane L. Schneider, MD, MSc University of California, San Diego

3 Learning Objectives Identify patients at high risk for osteoporotic fracture Individualize risk assessment including use of the WHO FRAX ® tool Discuss general measures to optimize calcium, vitamin D, and exercise Evaluate the different pharmacologic therapies to match the patient’s clinical situation Utilize different modalities to improve adherence and compliance with treatment plan

4 Osteoporosis Systemic skeletal disorder of compromised bone strength increased risk of fracture –34 million Americans: low bone mass –10 million Americans: osteoporosis 1 in 2 women and 1 in 4 men >age 50 will have an osteoporosis-related fracture in their lifetime By 2020, 1 in 2 Americans >age 50 will be at risk for fractures from osteoporosis or low bone mass US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; Available at: Accessed September 13, 2013.

5 2 million bone breaks a year (“2 million 2 many”) 1 Only 2 in 10 patients with osteoporosis get a follow-up test or treatment for osteoporosis 1 Fractures may have serious consequences 2 –Hip fracture 10%-20% additional mortality per year 20% of hip fracture patients require long-term nursing home care Only 40% fully regain their pre-fracture level of independence 1 Fracture Facts! 1. National Bone Health Alliance. 2 Million 2 Many. Available at: Accessed September 13, US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; Available at: Accessed September 13, 2013.

6 Underdiagnosed and Undertreated Underdiagnosed: National Osteoporosis Risk Assessment (NORA) study (200,160 postmenopausal women) 1 –40% osteopenic –7% osteoporotic –11% ≥1 fracture after age 45 years Undertreated: women meeting criteria for treatment 2 –15.7% not taking calcium –18.6% not taking vitamin D –52.7% not exercising >2 hrs per week –35.3% not receiving therapy 1. Siris ES, et al. JAMA. 2001;286: Schnatz PF, et al. Menopause. 2011;18:

7 The Clinical Challenge Often asymptomatic 1 –Until fracture occurs 1 –Even after some fractures (eg, 2/3 of vertebral fractures are asymptomatic) 2 The challenge to clinicians 1 : –Identify patients at high risk for fracture –Prevent first fracture 1. South-Paul JE. Am Fam Physician. 2001;63: Lenchnik L, et al. AJR. 2004;183:

8 Sharon 62-year-old White female 5′4″; 150 lbs 10 years postmenopause DXA performed 4 years ago –Spine T-score: -2.1 –Right hip T-score (of neck): -1.6

9 Personal History - Sharon Her mother suffered hip fracture in her 70s Performs weight-bearing exercise 3 times per week Nonsmoker Rarely drinks alcohol Takes 1 calcium supplement each day – unknown dose Consumes no dairy products and no vitamin D

10 Sharon Worried because of family history — What is the next step?

11 Optimizing Fracture Prevention in Primary Care Identifying patients at high risk Individualized risk assessment Management strategies –Nonpharmacologic modalities –Pharmacologic therapy –Modalities to improve adherence and compliance

12 The Good News Excellent diagnostic tools –Bone densitometry with DXA – noninvasive test –FRAX ® – new tool to help with management decisions in patients with reduced bone mineral density Effective and safe treatments National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Available at: Accessed September 13, 2013.

13 Strong Relationship Between Bone Density and Bone Strength Bone density accounts for 60% to 80% of bone strength in untreated patients 1 Best early predictor of fracture risk 2 Permits diagnosis before fractures T-score Relative Risk of Hip Fracture Kushida K. Clin Calcium. 2004;14: Fogelman J, Blake GM. J Nucl Med. 2000;41:

14 10-Year Probability of Symptomatic Fracture (%) Age Is a Major Risk Factor for Fracture With kind permission from Springer Science+Business Media: Kanis JA,et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int.2001;12: Adapted from Fig. 3. © 2001 International Osteoporosis Foundation and National Osteoporosis Foundation AGE Age 50 T-score % Fx Risk Age 70 T-score % Fx Risk -3-2

15 2010 Guidelines for Bone Density Testing 1. Adapted from National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Available at: Accessed September 13, US Preventive Services Task Force. Ann Intern Med. 2002;137: Screening –All women age 65 and older 1,2 –All men age 70 and older 1 Test postmenopausal women and men >50 if 1 : –Fracture after age 50 –Clinical risk factors for osteoporosis –Conditions/medications associated with bone loss o COPD, RA, hyperparathyroidism, celiac disease, IBD o Oral glucocorticoids, anticonvulsants, proton pump inhibitors, SSRIs, aromatase inhibitors

16 Majority of Fractures Occur in Patients With Osteopenia, Not Osteoporosis! Why? Osteopenia patients outnumber those with osteoporosis 3:1 Fracture risk—determined by more than just BMD Clinical factors such as age, lifestyle, and family and personal medical history also play a role Implications Appropriate treatment depends on being able to accurately determine the risk of future fractures Davey DA. S Afr Med J. 2012;102:

17 10-year risk of fractures: ≥3% for hip fracture or ≥20% for a major osteoporotic fracture T-scores between -1.0 and -2.5 and NOF Guidelines 2010: Whom to Treat After exclusion of secondary causes, treat postmenopausal women and men age 50 and older who have… Osteoporosis Clinical diagnosis: Hip or spine fracture DXA diagnosis: T-score -2.5 or below in the spine or hip National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Available at: Accessed September 13, 2013.

18 FRAX ® Statistically robust fracture risk prediction tool developed by the WHO for world-wide use Combines BMD + clinical risk factors to predict fracture risk better than either alone Predicts the 10-year probability of major osteoporotic fracture –Hip, spine, wrist, or humerus Use when the decision to treat is uncertain WHO FRAX ® Tool. Accessed September 13, 2013.

19

20

21 Answering Risk Factor Questions in FRAX ® 1.1. National Osteoporosis Foundation. FRAX ® Implementation Guide. Available at: content/uploads/2012/10/FRAXImplementationGuide_000.pdf. Accessed September 13, Kanis J, et al. Osteoporosis Int. 2005;16: Prior fracture Denotes a previous adult fracture after age 40 occurring with little or no trauma – fractures of face, fingers, toes excluded 1 Systemic corticosteroids Best applies to current or long-term past use of oral steroids (≥5 mg/day prednisone equivalent for ≥3 months) 1,2

22 Select DXA manufacturer and enter BMD (g/cm 2 ) Use Femoral Neck Bone Mineral Density (BMD) only FRAX ® Caveats: Entering Bone Density Data

23 NOF Guidelines: ≥20% major fx ≥3% hip fx

24 Benefits of FRAX ® Treatment decisions in osteopenic patients clearer –Decision is based on the risk of fracture, not T-score alone Identifies patients at high-risk for fractures to ensure that they are offered treatment to lower their risk Helps avoid giving medication to those who are at low risk and have little to gain from treatment National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Available at: Accessed September 13, “Specific treatment decisions must be individualized”

25 When Clinical Judgment Is Needed FRAX ® may underestimate fracture risk: Some risk factors (glucocorticoids, smoking, alcohol, fractures) are dose dependent, but FRAX ® can’t consider dose Some risk factors that increase the risk of fractures independently of their effect on BMD are not included in FRAX ® : –Falls –Frailty –Some diseases and medications (immobilization, diabetes, anticonvulsants, SSRIs, PPIs, TZDs) National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Available at: Accessed September 13, 2013; Gnudi S, et al. J Bone Miner Res. 2001;16: ; Nguyen TV, et al. J Bone Miner Res. 2005;20: ; Sornay-Rendu E, et al. J Bone Miner Res. 2005;20:

26 Be on the Lookout for Silent Fractures 65-year-old, T-score -1.6 Height measurement: 2.5″ loss from her young adult height; lateral spine x-ray ordered Vertebral Fractures: 2/3 unrecognized by patients/clinicians Indicate very high risk for future spine and hip fractures Are a major indication for pharmacotherapy Consider Vertebral Fracture Assessment (VFA) if vertebral fracture is suspected clinically Xu WW, et al. Bone. 2011;2: National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Available at: Accessed September 13, 2013.

27 Identifying High-risk Patients in Clinical Practice – Summary Primary goal: fracture prevention-therefore, select patients based on risk of fracture Pharmacologic Therapy – Patients with osteoporosis by DXA OR – With a history of hip or spine fractures FRAX ® – Quantitative risk assessment – Helps communicate risk to patients – May increase treatment of high-risk patients and decrease treatment of low-risk patients

28 Osteoporosis Management Nonpharmacologic Pharmacologic

29 Challenges With Current Treatment Approaches Bone loss per se asymptomatic Patients may not appreciate fracture prevention No treatment agent meets the ideal profile— inexpensive, easy to take, uniformly effective, entirely free of risk Perceived risk of therapy may outweigh perceived benefit Patient motivation to “adhere” and “persist” with therapy may vary

30 Calcium Intake Recommendations From the IOM Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D: Report Brief. Washington, DC: IOM ; Available at: Accessed September 13, Life Stage Group Estimated Requirement (mg/day) Recommended Dietary Allowance (mg/day) Upper Level Intake (mg/day) Infants 0 to 6 months** 1,000 Infants 6 to 12 months**1,500 1–3 years old ,500 4–8 years old8001,0002,500 9–13 years old1,1001,3003,000 14–18 years old1,1001,3003,000 19–30 years old8001,0002,500 31–50 years old8001,0002,500 51–70 year-old male8001,0002,000 51–70 year-old female1,0001,2002,000 >70 years old1,0001,2002,000 * For infants, adequate intake is 200 mg/day for 0 to 6 months of age and 260 mg/day for 6 to 12 months of age.

31 Vitamin D Intake Recommendations From the IOM Life Stage Group Estimated Avg Requirement (IU/day) Recommended Dietary Allowance (IU/day) Upper Level Intake (IU/day) Infants 0 to 6 months **1.000 Infants 6 to 12 months **1,500 1–3 years old ,500 4–8 years old ,000 9–13 years old ,000 14–18 years old ,000 19–30 years old ,000 31–50 years old ,000 51–70-year-old male ,000 51–70-year-old female ,000 >70 years old ,000 Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D: Report Brief. Washington, DC: IOM; Available at: Accessed September 13, * For infants, adequate intake is 400 IU/day for 0 to 6 months of age and 400 IU/day for 6 to 12 months of age.

32 Benefits of Exercise What type? –Weight-bearing –Muscle-strengthening Expected benefits? –Small (1% to 2%) effect on adult BMD –Reduces the loss of muscle mass –May reduce risk of falls by improving strength and balance –Regular walking decreases risk of hip fractures Centers for Disease Control and Prevention. Injury Center.

33 Exercise – Some Caveats –Patients may have nonskeletal factors that increase the risk of falls and fractures Visual contrast sensitivity and depth perception 1 Women with wrist fractures—increased risk of future fractures 1 –Forward flexion of spine and lifting can be problematic 2,3 Low BMD in spine History of vertebral fractures 1. Edwards BJ, et al. Age Ageing. 2006;35: Sinaki M. Pain Pract. 2013;13(1): Myers ER, Wilson SE. Spine. 1997;22(24 Suppl):25S-31S.

34 Pharmacologic Options

35 PreventionTreatment FDA-Approved Therapeutic Options Estrogen Alendronate Risedronate Ibandronate Zoledronic acid Raloxifene Calcitonin PTH (teriparatide) Denosumab

36 Antiresorptive Decrease bone resorption Most treatment agents Examples: Bisphosphonates, SERMs, calcitonin, estrogen, denosumab Anabolic Stimulate bone formation Example: teriparatide Antiresorptive and Anabolic Therapies

37 Estrogen Treatment (ET) Several approved oral and transdermal preparations Treats symptoms of estrogen deficiency Skeletal effects: – Decrease in biochemical markers of 50% to 60% – 2-year BMD increase of 4% to 6% at hip and spine – Decreased incidence of vertebral and hip fractures (34%) after 5 years in the Women’s Health Initiative (WHI) – Effects in women with osteoporosis have not been evaluated in randomized controlled trials Concern about adverse effects Long-term use not recommended Rossouw JE, et al. Writing Group for the Women’s Health Initiative Investigators. JAMA. 2002;288:

38 The Concept of a SERM Selective Estrogen Receptor Modulator (EAAs: Estrogen Agonist/Antagonists) Binds to the estrogen receptors Produces an estrogen agonist effect in some tissues Produces an estrogen antagonist effect in others

39 Raloxifene Raloxifene (60 mg daily) Skeletal effects: – Decrease in biochemical markers of 30% – 3-year BMD increases of 2% to 3% at hip and spine – Decreased incidence of vertebral fractures (30% to 50%) in women with pre-existing vertebral fractures or low bone density. No effect on nonvertebral or hip fractures has been observed Extra-skeletal effects: reduction in invasive breast cancer Ettinger B, et al. JAMA. 1999;282:

40 Raloxifene Adverse effects –Hot flashes –2- to 3-fold increased risk of venous thromboembolic events –No increased risk of stroke, but Black Box Warning for increased risk of death following stroke –Leg cramps Sontag A, Wan X, Krege JH. Curr Med Res Opin. 2010;26:71-76.

41 Calcitonin Calcitonin (200 units daily by nasal spray) Skeletal effects: – Decrease in biochemical markers of 20% – Small effect (1% to 2%) on bone density in spine – Reduced incidence of vertebral fractures (36%) in women with pre- existing vertebral fractures – No effect on nonvertebral or hip fractures has been observed Adverse effects – Nasal stuffiness – Possible increased cancer risk Chesnut CH 3d, et al. Am J Med. 2000;109: Accessed: September 13, European Medicines Agency. Press release. July 20, Available at: Accessed: September 13, 2013.

42 Bisphosphonates Alendronate, Risedronate, Ibandronate, and Zoledronic Acid Alendronate: 10 mg daily (tablet) or 70 mg weekly (tablet or liquid) for treatment, 5 mg daily or 35 mg weekly for prevention Risedronate: 5 mg daily or 35 mg weekly (tablet); 150 mg monthly (tablet) Ibandronate: 150 mg monthly by tablet; 3 mg intravenously over 15 to 30 seconds every 3 months Zoledronic acid: 5 mg by intravenous infusion over a minimum of 15 minutes once every year for treatment—and every other year for prevention * 2012 Jun 25;172(12):930-6 National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Available at: Accessed September 13, 2013.

43 Bisphosphonates: Indications Treatment and prevention of postmenopausal osteoporosis –Alendronate, risedronate, ibandronate, zoledronic acid Prevention and/or treatment of glucocorticoid- induced osteoporosis –Risedronate, zoledronic acid, alendronate Treatment of men with low bone density –Alendronate, risedronate, zoledronic acid

44 Increased bone density in the spine by 5% to 8% and at the hip by 3% to 6% after 3 years Reduced incidence of vertebral fractures by 40% to 70% Alendronate, risedronate and zoledronic acid reduced non-vertebral fractures (25% to 40%), including hip fractures (40% to 60%), in women with osteoporosis Ibandronate: Overall, no effect observed on non-vertebral or hip fractures. In a post-hoc analysis, non-vertebral fracture reduction was seen in a high-risk subgroup with a baseline femoral neck T-score less than -3.0 Bisphosphonates: Effects Alendronate, Risedronate, Ibandronate and Zoledronic Acid

45 Contraindications/Warnings/Precautions –Hypocalcemia –Creatinine clearance <30 cc/min (<35 cc/min for zoledronic acid) –For oral dosing: Esophageal stricture or impaired esophageal motility (alendronate); inability to stand or sit for at least 30 minutes (alendronate/risedronate) or 60 minutes (ibandronate) Notes: UGI symptoms per se are not a contraindication to oral dosing. Use in pregnancy: Class C Oral dosing requirements –Tablets (with exception of delayed release risedronate) taken on an empty stomach after overnight fast with 6 to 8 oz of plain water while in an upright position –Patients should not eat or lie down for at least 30 minutes (alendronate and risedronate) or 60 minutes (ibandronate) –Calcium and vitamin D supplements, if needed, should be taken at a different time of day than the oral bisphosphonate Bisphosphonates National Osteoporosis Foundation. Med Lett. 2011;53(1360):24.

46 “Class warning” regarding UGI symptoms (no increase in UGI complaints in randomized controlled trials) Influenza-like symptoms may occur after first monthly oral dose of IV bisphosphonate “Class warning” regarding infrequent bone, joint, and/or muscle pain “Class warning” regarding jaw osteonecrosis “Class warning” about atypical fractures following long-term therapy Bisphosphonates: Side Effects

47 “Osteonecrosis” of the Jaw (ONJ) An area of exposed alveolar or palatal bone that typically shows poor healing over several months –95% of cases have been reported with high-dose, chronic IV bisphosphonate treatment of myeloma and cancer metastatic to bone 1 –Can occur with denosumab 2 –Pain in 2/3 cases: infection may or may not be present –Known risk factors: invasive dental procedures, oral trauma, periodontitis, poor oral hygiene, radiotherapy to the jaw, chemotherapy, corticosteroids, infection –Pathogenesis is not known 3 1. Woo SB, et al. Ann Intern Med. 2006;144: Sutton EE, Riche DM. Ann Pharmacother. 2012;46: Khosla S, et al. J Bone Miner Res. 2007;22:

48 Atypical Fractures of Femur in Patients Taking Anti-Resorptive Agents Long Term Park-Wyllie LY, et al. JAMA. 2011;305: Shane E, et al. J Bone Miner Res May 28. [Epub ahead of print]. Watts NB, Diab DL. J Clin Endocrinol Metab. 2010;95: Meier RP. Arch Intern Med. 2012;172: May begin with stress reaction or stress fracture of lateral femoral cortex (A) Transverse fractures of femoral diaphysis or in subtrochanteric region (B) Often bilateral Prodromal pain in thigh or groin in 70% Occurs in untreated patients, but increased incidence with long-term antiresorptive therapy, particularly bisphosphonates and denosumab

49 FDA Safety Update Be aware of the possibility of atypical fractures in patients taking bisphosphonates Evaluate any patient who presents with new groin or thigh pain to rule out fracture of the femoral shaft Discontinue potent antiresorptive medication in patients with atypical fractures Periodic reevaluation of need to continue bisphosphonate therapy, particularly in patients treated > 5 years FDA. MedWatch Online Voluntary Reporting Form. https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm. Accessed: September 13, Whitaker M, et al. N Engl J Med. 2012;366(22):

50 Bisphosphonate Therapy: “Long-Term” Treatment Stopping treatment in high-risk patients –After 5 years of alendronate-decline in BMD, rise in biochemical markers, no increased fracture risk except clinical vertebral fractures 1 –After 3 years of risedronate, spine BMD rose, vertebral facture risk was still reduced compared with control patients 2 –After 3 years of zoledronic acid, slight increase in morphometric fractures vs clinical vertebral fractures 3 Long-term treatment has not clearly been associated with safety issues or loss of efficacy Cessation of treatment after 2 to 5 years is associated with some persisting effect on biochemical markers, as well as BMD; this has been best characterized for alendronate and zoledronic acid 1. Black DM, et al. JAMA. 2006;296: Watts NB, et al. Osteoporosis Int. 2008;19: Black DM, et al. J Bone Miner Res. 2012;27:

51 Bisphosphonate Holidays In patients at high risk for fractures, continued treatment seems reasonable. Consider a drug holiday of 1 to 2 years after 10 years of treatment For lower risk patients, consider a “drug holiday” after 4 to 5 years of stability Follow BMD and bone turnover markers during a drug holiday period, and reinitiate therapy if bone density declines or markers increase Watts NB et al; AACE Osteoporosis Task Force. Endocr Pract. 2010;16(Suppl 3):1-37. Whitaker M, et al. N Engl J Med. 2012;366(22):

52 Denosumab Monoclonal antibody to RANKL 60 mg subcutaneous injection every 6 months 9% increase in spinal BMD after 3 years in the pivotal FREEDOM trial; 4% to 5% increase in hip BMD Reduction in fracture risk after 3 years: –68% decrease in new vertebral fractures –40% decrease in hip fractures –20% decrease in nonvertebral fractures 8-year data: continued increase BMD, reduced bone turnover, good safety Cummings SR, et al. N Engl J Med. 2009;368: Prolia (prescribing information). Thousand Oaks, CA: Amgen; June McClung MR, et al. Osteoporos Int. 2013;24(1):

53 Denosumab Adverse Events Adverse events that occurred more commonly in denosumab group (as listed in the PI): –Serious infections leading to hospitalization –Dermatitis, eczema, rashes –Back pain, pain in the extremity, musculoskeletal pain, hypercholesterolemia, cystitis –Pancreatitis –Osteonecrosis of the jaw –Significant suppression of bone remodeling Prolia (prescribing information). Thousand Oaks, CA: Amgen; June 2012.

54 Teriparatide: rhPTH [1-34] The only treatment agent that is anabolic—stimulates bone formation rather than inhibiting bone resorption 20 μg daily (subcutaneously) for no more than 2 years Indication: treatment of men and postmenopausal women with osteoporosis who are at high risk for fracture Effects: –Increased bone density in spine by 9% and hip by 3% vs placebo over 18 months –Reduced incidence of vertebral fractures (65%) and nonvertebral fragility fractures (53%) in women with pre-existing vertebral fractures –Studies too small to evaluate effect on hip fractures Adverse reactions: arthralgia, pain, nausea; warning about osteosarcoma risk in rats Neer RM, et al. N Engl J Med. 2001;344: Forteo (prescribing information). Indianapolis, IN: Eli Lilly and Company; March 21, 2012.

55 BMD Doesn’t Fully Predict the Reduction in Fracture Risk Antiresorptive treatment decreases fracture risk more rapidly and to a larger extent than one would predict from the relatively small changes in BMD 1 –Fracture protection can be observed in the absence of a significant change in BMD 2 Fracture protection persists even when the BMD reaches a plateau –BMD stability does not mean “nonresponse” 1.Harrington JT, et al. Calcif Tissue Int. 2004;74: Wasnich RD, Miller PD. J Clin Endocrinol Metab. 2000;85:

56 Safe and effective therapies are available Antiresorptive agents Prevent bone loss and preserve architecture Improve quality of bone Reduce the risk of vertebral fractures (all agents) Alendronate, risedronate, zoledronic acid, and denosumab proved to reduce the risk of nonvertebral and hip fractures Anabolic agent: rhPTH [1-34] (teriparatide) Increases bone density and size Improves quality of bone Reduces the risk of vertebral and nonvertebral fractures; no hip fracture data Patient factors determine the most appropriate drug to use Treatment: Summary

57 The right medication for the right patient at the right time Susceptibility to side effects –Past history of DVT – no estrogen or raloxifene –Esophageal stricture – use of IV bisphosphonates or denosumab Dosing/convenience Adherence Treatment Considerations

58 This winter, Sharon slipped on wet leaves and fell on the grass, fracturing her wrist How does the current fracture impact on clinical decision-making? Should Sharon have an updated DXA? Should any laboratory tests be requested? Sharon – Updated Medical History

59 62 DXA at age 58

60 Evaluation of the Patient With Osteoporosis Tannenbaum C, et al. J Clin Endocrinol Metab. 2002;87: % to 63% of patients with osteoporosis and/or fractures have been found to have previously unrecognized underlying disorders affecting bone (eg, vitamin D deficiency, hypercalciuria, calcium malabsorption, hyperthyroidism, multiple myeloma, etc) All patients need evaluation prior to initiation of pharmacologic therapy: –Careful history and examination –Lab testing o Chemistry (Ca, P, Alk Phos, Cr, LFT’s) o CBC o 24-hour urine calcium o 25 OH vitamin D o TSH if taking thyroid hormone or symptoms Sensitivity: 92%

61 Sharon Sharon’s laboratory tests are normal She considers her individualized risk, and chooses an antiresorptive agent Sharon does fairly well with her once- weekly agent for the first 3 months She fails to refill her prescription for several weeks Over the next several months, she often misses her weekly dose

62 Adherence to Treatment in Osteoporosis Patients

63 Most Patients Discontinue Oral Bisphosphonates Soon After Treatment Initiation Months Following Therapy Initiation Percent Adherent on Weekly Bisphosphonate Rapid drop in persistence due to nonacceptance Further decrease in persistence due to multiplicity of factors With permission from Springer Science+Business Media: Weycker D, et al. Compliance with drug therapy for postmenopausal osteoporosis, Osteoporos Int, 2006;17: Figure 1. © International Osteoporosis Foundation and National Osteoporosis Foundation 2006.

64 Adherence With Osteoporosis Therapies Clinical trials –Good adherence (usually >80%) –Significant reduction in risk of vertebral, nonvertebral, and hip fractures 1 Real-world adherence is poor –Up to 83% of patients nonadherent with prescribed osteoporosis Rx 2-4 –Poor correlation was reported between patient and physician perceptions of compliance Consequences of poor adherence –Magnitude of risk reduction for hip and vertebral fractures lower than expected 4,5 1. Siris ES, et al. Am J Med. 2009;122(2 suppl):S3-S Hamilton B, et al. Osteoporos Int. 2003;14: Yood RA, et al. Osteoporos Int. 2003;14: Caro JJ, et al. Osteoporos Int. 2004;15: Eastell R, et al. Calcif Tissue Int. 2003;72:408. Abstract P-297.

65 Why Do Patients Resist Change? Historically, several notions have been proposed as to why patients struggle with adherence to treatment plans: –Denial or lack of insight –Lack of knowledge –Lack of skills –Lack of caring Butterworth SW. J Manag Care Pharm. 2008;14(6 Suppl S-b):S21-S25.

66 Improving Adherence Assess patient beliefs/understanding Understand current medication use patterns Identify patients likely to be nonadherent

67 Impact of Lack of Patient Education Did not always give them adequate information about their medications Did not communicate this information in a format that was easy to comprehend Lau E, et al. Can Fam Physician. 2008;54: In Canadian study of postmenopausal osteoporotic patients said their doctors Lack of communication with the HCP was perceived to be a major factor affecting adherence

68 Side Effects and Adherence Discuss side effects of the medicines Put into perspective of risk vs benefits Reiterate patient's high risk of fracture Address other information sources (media, Internet, friends) –May deter from starting –Encourage to stop use

69 Motivational Interviewing Open-ended Express empathy Roll with resistance Support autonomy Explore ambivalence Create an action plan Butterworth SW. J Manag Care Pharm. 2008;14(6 suppl S6):S Solomon DH, et al. Osteoporos Int. 2010;21:

70 Patient-Centered Medical Home (PCMH): Osteoporosis Management Practice Organization Around osteo management IMPROVED OUTCOMES Quality Measures Optimizing FX prevention Health IT Pt reminders Pt support, tx Family Medicine Patient ExperienceSupportAdherence

71 Summary of Optimal Osteoporosis Management Utilize tools to identify high-risk patients Target any patient with a fracture for evaluation Ensure adequate calcium and vitamin D Promote physical activity Discuss medicine options with high-risk patients Remove barriers to adherence

72 Introduction to Osteoporosis PI Activity

73 Questions


Download ppt "Planning Committee Cheryl Lambing, MD, Co-Chair UCLA / Ventura County Medical Center Marjorie Luckey, MD, Co-Chair Saint Barnabas Medical Center Steven."

Similar presentations


Ads by Google